Steve E. Krognes, Director at Denali Therapeutics Inc. (DNLI), sold 30,000 shares at $20.25 ($608K) on 2024-12-31, disclosed to the SEC on 2025-01-03.
Scheduled sale ($608k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| DNLI | SELL | 2025-01-08 | $139K | — | Filing → |
| DNLI | SELL | 2024-10-02 | $871K | — | Filing → |
| DNLI | SELL | 2024-08-22 | $41K | — | Filing → |